229 related articles for article (PubMed ID: 23949153)
21. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
22. The cost effectiveness of tamoxifen in the prevention of breast cancer.
Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
[TBL] [Abstract][Full Text] [Related]
23. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
[TBL] [Abstract][Full Text] [Related]
24. Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Younis T; Rayson D; Dewar R; Skedgel C
Ann Oncol; 2007 Feb; 18(2):293-8. PubMed ID: 17095569
[TBL] [Abstract][Full Text] [Related]
25. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Skedgel C; Rayson D; Dewar R; Younis T
Breast Cancer Res Treat; 2007 Mar; 101(3):325-33. PubMed ID: 16897433
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil.
Fonseca M; Araújo GT; Saad ED
Rev Assoc Med Bras (1992); 2009; 55(4):410-5. PubMed ID: 19750307
[TBL] [Abstract][Full Text] [Related]
27. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
[TBL] [Abstract][Full Text] [Related]
28. A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer.
John-Baptiste AA; Wu W; Rochon P; Anderson GM; Bell CM
PLoS One; 2013; 8(5):e62614. PubMed ID: 23671612
[TBL] [Abstract][Full Text] [Related]
29. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.
Frederix GW; van Hasselt JG; Schellens JH; Hövels AM; Raaijmakers JA; Huitema AD; Severens JL
Pharmacoeconomics; 2014 Jan; 32(1):47-61. PubMed ID: 24263964
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
Karnon J; Delea T; Johnston SR; Smith R; Brandman J; Sung J; Goss PE
Pharmacoeconomics; 2006; 24(3):237-50. PubMed ID: 16519546
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
Erman A; Nugent A; Amir E; Coyte PC
Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
[TBL] [Abstract][Full Text] [Related]
32. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Skedgel C; Rayson D; Dewar R; Younis T
Breast; 2007 Jun; 16(3):252-61. PubMed ID: 17207623
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women.
Smith TJ; Hillner BE
J Clin Oncol; 2000 Jan; 18(2):284-6. PubMed ID: 10637241
[TBL] [Abstract][Full Text] [Related]
34. Understanding tamoxifen adherence in women with breast cancer: A qualitative study.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Br J Health Psychol; 2017 Nov; 22(4):978-997. PubMed ID: 28850763
[TBL] [Abstract][Full Text] [Related]
35. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
36. [Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer].
Gamboa O; Díaz S; Chicaíza L; García M
Biomedica; 2010; 30(1):46-55. PubMed ID: 20890549
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
Simons WR; Jones D; Buzdar A
Clin Ther; 2003 Nov; 25(11):2972-87. PubMed ID: 14693319
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
Gelber RD; Cole BF; Goldhirsch A; Rose C; Fisher B; Osborne CK; Boccardo F; Gray R; Gordon NH; Bengtsson NO; Sevelda P
Lancet; 1996 Apr; 347(9008):1066-71. PubMed ID: 8602056
[TBL] [Abstract][Full Text] [Related]
39. More than just side-effects: The role of clinical and psychosocial factors in non-adherence to tamoxifen.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Br J Health Psychol; 2017 Nov; 22(4):998-1018. PubMed ID: 28940998
[TBL] [Abstract][Full Text] [Related]
40. A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients.
Karnon J; Jones T
Pharmacoeconomics; 2003; 21(7):513-25. PubMed ID: 12696991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]